Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study

BACKGROUND: Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐mutation or anaplastic lymphoma kinase (ALK)‐rearrangement. However, the real‐world evaluation stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hongge, Song, Xia, Zhang, Yuhui, Zhang, Shucai, Li, Fang, Fang, Jian, Li, Junling, Liang, Li, Nie, Ligong, Ma, Kewei, Zhang, Liangming, Wang, Xiaohong, Xu, Junjun, Wei, Yanxia, Wang, Jinghui, Song, Qi, Tian, Guangming, Mu, Yuxin, Gu, Yangchun, Yang, Lei, Sun, Ping, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610253/
https://www.ncbi.nlm.nih.gov/pubmed/31144459
http://dx.doi.org/10.1111/1759-7714.13090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610253/
https://www.ncbi.nlm.nih.gov/pubmed/31144459
http://dx.doi.org/10.1111/1759-7714.13090

Ejemplares similares